N-Acetyl-Cysteine Reduces Flu 54 Percent
By Michael Mooney

N-Acetyl-Cysteine ( NAC), taken at 600 mg, two per day (1200 mg per day) has been shown to significantly reduce the incidence and severity of the flu by about 54 percent in a six month study of 262 adults.

NAC also has valuable implications as an anti-disease and anti-aging supplement because of its support of antioxidant mechanisms in the body. NAC also improves cell-mediated immunity, which helps control invading organisms, like viruses. NAC converts into glutathione peroxidase, an important detoxifying antioxidant enzyme that the liver uses to detoxify.

Title: Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. S. De Flora, C. Grassi, L. Carati. European Respiratory Journal 1997; 10:1535–1541.

ABSTRACT: N-acetylcysteine (NAC), an analogue and precursor of reduced glutathione, has been in clinical use for more than 30 yrs as a mucolytic drug. It has also been proposed for and/or used in the therapy and/or prevention of several respiratory diseases and of diseases involving oxidative stress, in general. The objective of the present study was to evaluate the effect of long-term treatment with NAC on influenza and influenza-like episodes.

A total of 262 subjects of both sexes (78% ≥65 yrs, and 62% suffering from nonrespiratory chronic degenerative diseases) were enrolled in a randomized, doubleblind trial involving 20 Italian Centres. They were randomized to receive either placebo or NAC tablets (600 mg) twice daily for 6 months. Patients suffering from chronic respiratory diseases were not eligible, to avoid possible confounding by an effect of NAC on respiratory symptoms.NAC treatment was well tolerated and resulted in a significant decrease in the frequency of influenza-like episodes, severity, and length of time confined to bed.Both local and systemic symptoms were sharply and significantly reduced in the NAC group. Frequency of seroconversion towards A/H1N1 Singapore 6/86 influenza virus was similar in the two groups, but only 25% of virus-infected subjects under NAC treatment developed a symptomatic form, versus 79% in the placebo group.Evaluation of cell-mediated immunity showed a progressive, significant shift from anergy to normoergy following NAC treatment. Administration of N-acetylcysteine during the winter, thus, appears to provide a significant attenuation of influenza and influenza-like episodes, especially in elderly high-risk individuals. N-acetylcysteine did not prevent A/H1N1 virus influenza infection but significantly reduced the incidence of clinically apparent disease.

Michael Mooney
www.michaelmooney.net